These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17934518)

  • 1. Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.
    Perazzona B; Lin H; Sun T; Wang Y; Arlinghaus R
    Oncogene; 2008 Apr; 27(15):2208-14. PubMed ID: 17934518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.
    Klucher KM; Lopez DV; Daley GQ
    Blood; 1998 May; 91(10):3927-34. PubMed ID: 9573031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
    Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
    Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
    Tao WJ; Lin H; Sun T; Samanta AK; Arlinghaus R
    Oncogene; 2008 May; 27(22):3194-200. PubMed ID: 18071309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Chu S; Li L; Singh H; Bhatia R
    Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Bcr serine kinase by tyrosine phosphorylation.
    Liu J; Wu Y; Ma GZ; Lu D; Haataja L; Heisterkamp N; Groffen J; Arlinghaus RB
    Mol Cell Biol; 1996 Mar; 16(3):998-1005. PubMed ID: 8622703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
    Cortez D; Kadlec L; Pendergast AM
    Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
    Gishizky ML; Cortez D; Pendergast AM
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
    Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
    Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase.
    Wu Y; Liu J; Arlinghaus RB
    Oncogene; 1998 Jan; 16(1):141-6. PubMed ID: 9467953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
    Mitra A; Sasikumar K; Parthasaradhi BV; Radha V
    Biochim Biophys Acta; 2013 Jan; 1832(1):275-84. PubMed ID: 23124138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
    Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
    Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.